STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

Point72 and Steven A. Cohen Report 6.7% Ownership in KALA BIO

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

KALA BIO, Inc. Schedule 13G reports that Point72-related filers — Point72 Asset Management, Point72 Capital Advisors, Inc., and Steven A. Cohen — jointly disclose beneficial ownership of 469,229 shares of KALA common stock, representing 6.7% of the class as of the close of business on September 10, 2025. The filing states Point72 Asset Management and Point72 Capital Advisors exercise shared voting and dispositive power over these shares through Point72 Associates, an investment fund they manage. The filing includes a Joint Filing Agreement (Exhibit 99.1) and affirms the shares were not acquired to influence control of the issuer.

Positive

  • Disclosure of a 6.7% position by Point72 and Steven A. Cohen provides transparency about a material holder in KALA
  • Joint Filing Agreement (Exhibit 99.1) standardizes reporting and clarifies the reporting parties
  • Filing certifies no intent to change control, which clarifies the current purpose of the holdings

Negative

  • None.

Insights

TL;DR: Point72 disclosures show a meaningful 6.7% stake in KALA, signaling a notable position but no stated intent to change control.

The filing documents an institutional ownership position of 469,229 shares (6.7%), disclosed under Rule 13d-1(c)/(d) conventions with shared voting and dispositive powers. For investors, this quantifies a concentrated stake by a well-known asset manager and its principal, which could affect liquidity or signal conviction in corporate prospects. The statement explicitly denies acquisition for control, limiting immediate governance implications, though the position is large enough to merit monitoring for future schedule updates or activity.

TL;DR: Joint filing documents coordinated reporting and control channels but disclaims control intent; position size may influence engagement opportunities.

The Schedule 13G shows coordinated reporting by Point72 entities and Steven A. Cohen, with shared voting/dispositive power over the reported shares and a Joint Filing Agreement filed as Exhibit 99.1. The filer’s certification excludes an intent to influence control, aligning this with passive or investment-adviser reporting norms rather than active activist behavior. Given the >5% threshold, the issuer and shareholders should note the identity of the holder for any future governance outreach or market disclosures.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Point72 Asset Management, L.P.
Signature:/s/ Jason M. Colombo
Name/Title:Jason M. Colombo, Authorized Person
Date:09/11/2025
Point72 Capital Advisors, Inc.
Signature:/s/ Jason M. Colombo
Name/Title:Jason M. Colombo, Authorized Person
Date:09/11/2025
STEVEN A. COHEN
Signature:/s/ Jason M. Colombo
Name/Title:Jason M. Colombo, Authorized Person
Date:09/11/2025
Exhibit Information

Exhibit 99.1: Joint Filing Agreement

FAQ

What stake does Point72 report in KALA (KALA)?

Point72 Asset Management, Point72 Capital Advisors, and Steven A. Cohen report beneficial ownership of 469,229 shares, representing 6.7% of KALA common stock as of September 10, 2025.

Who holds voting and dispositive power over the reported KALA shares?

The filing states shared voting power and shared dispositive power of 469,229 shares, exercised through Point72 Asset Management and Point72 Capital Advisors with respect to Point72 Associates.

Does the Schedule 13G indicate Point72 intends to influence control of KALA?

No. The certification in Item 10 states the securities were not acquired and are not held to change or influence control of the issuer.

When is the ownership information reported effective?

The ownership information is stated as of the close of business on September 10, 2025, and the form reflects the event date of September 4, 2025.

Where is Point72’s principal business address listed?

The filing lists the principal business office for Point72 and Mr. Cohen as 72 Cummings Point Road, Stamford, CT 06902.
Kala Pharmaceuticals Inc

NASDAQ:KALA

KALA Rankings

KALA Latest News

KALA Latest SEC Filings

KALA Stock Data

7.47M
8.04M
1.75%
51.86%
5.98%
Biotechnology
Pharmaceutical Preparations
Link
United States
ARLINGTON